<DOC>
	<DOCNO>NCT02034435</DOCNO>
	<brief_summary>Aim 1.Test hypothesis activation endogenous renin-angiotensin-aldosterone system impairs glycemic control via effect insulin sensitivity insulin secretion . Aim 2 . Test hypothesis activation endogenous renin-angiotensin-aldosterone system impairs insulin secretion insulin sensitivity via mineralocorticoid-receptor dependent mechanism .</brief_summary>
	<brief_title>Endogenous Renin-Angiotensin-Aldosterone System Glucose Metabolism</brief_title>
	<detailed_description>In aim 1 subject randomize cross 8 day high salt 8 day low salt diet assessment make . In aim 2 , subject randomize 2x2 cross study 8 day low salt diet either eplerenone 50mg amlodipine 5mg .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Ambulatory subject , 18 70 year age , inclusive 2 . For female subject , follow condition must meet : 1. postmenopausal status least 1 year , 2. statuspost surgical sterilization , 3. childbearing potential , utilization adequate birth control willingness undergo urine betahcg test prior drug treatment every study day . 3 . Metabolic Syndrome define presence &gt; 3 follow : 1 . Systolic Blood Pressure &gt; 130 mm Hg OR Diastolic Blood Pressure &gt; 85 mm Hg . 2 . Glucose Intolerance ( Fasting Plasma Glucose â‰¥ 100 mg/dL ) 3 . Increased triglyceride level &gt; 150mg/dL ( 1.7mmol/L ) 4 . Decreased level HDL cholesterol ( For male , less 40 mg/dL ; For female , less 50 mg/dL ) 5 . Waist circumference ( For male , great 40 inch ; For female , great 35 inch ) 1. type 1 Diabetes 2 . Type II Diabetes 3 . Impaired renal function 4 . Prior allergy medication use study protocol 5 . Screening plasma potassium &gt; 5.5 mmol/L sodium &lt; 135 mmol/L 6 . Cardiovascular disease 7 . Use hormone replacement therapy 8 . Breastfeeding 9 . Treatment anticoagulants 10 . History serious neurologic disease 11 . History presence immunological hematological disorder 12 . Diagnosis asthma require use inhale beta agonist 13 . Clinically significant gastrointestinal impairment 14 . Impaired hepatic function 15 . Hematocrit &lt; 35 % 16 . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult , arthritis treat nonsteroidal antiinflammatory drug 17 . Treatment chronic systemic glucocorticoid therapy 18 . Treatment lithium salt 19 . History alcohol drug abuse 20 . Treatment investigational drug 1 month precede 21 . Mental condition render subject unable understand nature , scope possible consequence study 22 . Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>